"Muscarinic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
| Descriptor ID |
D018727
|
| MeSH Number(s) |
D27.505.519.625.120.200.500 D27.505.696.577.120.200.500
|
| Concept/Terms |
Muscarinic Antagonists- Muscarinic Antagonists
- Antagonists, Muscarinic
- Antimuscarinics
- Antimuscarinic Agents
- Agents, Antimuscarinic
- Cholinergic Muscarinic Antagonists
- Antagonists, Cholinergic Muscarinic
- Muscarinic Antagonists, Cholinergic
|
Below are MeSH descriptors whose meaning is more general than "Muscarinic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Muscarinic Antagonists".
This graph shows the total number of publications written about "Muscarinic Antagonists" by people in this website by year, and whether "Muscarinic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 25 | 7 | 32 |
| 2018 | 23 | 7 | 30 |
| 2019 | 6 | 3 | 9 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Muscarinic Antagonists" by people in Profiles.
-
Remote Pediatric Ophthalmology and Adult Strabismus during the COVID-19 Pandemic. J Binocul Vis Ocul Motil. 2021 Jul-Sep; 71(3):110-117.
-
Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2021 06 23; 78(13):1184-1194.
-
Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry. PLoS One. 2021; 16(6):e0252576.
-
Statement from the Japanese Respiratory Society: Working diagnosis and initial management of COPD during the COVID-19 pandemic. Respir Investig. 2021 Jul; 59(4):385-388.
-
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020 11; 8(11):1106-1120.
-
Anticipatory prescribing in community end-of-life care in the UK and Ireland during the COVID-19 pandemic: online survey. BMJ Support Palliat Care. 2020 Sep; 10(3):343-349.
-
Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020 May; 58(3):155-168.
-
A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019 11; 13(11):1079-1085.
-
Cost saving of switching to equivalent inhalers and its effect on health outcomes. Thorax. 2019 11; 74(11):1078-1086.
-
Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. JAMA. 2019 05 07; 321(17):1693-1701.